Wuhan YZY Medical Science and Technology Co.,Ltd.

About YZY MED

About YZYMED

Founded in July 2011, with personalized diagnosis and treatment of cardiovascular, tumor as the strategic direction, Wuhan YZY Medical Science and Technology Co., Ltd. (YZY Med)is a high-tech enterprise specializing in the R&D, production and sales of individualized medical diagnostic products. The company has established various technical platforms, including ARMS fluorescence quantitative PCR, multiple fluorescence quantitative PCR, nucleic acid mass spectrometry, fluorescence in situ hybridization(FISH) and circulating tumor cell detection, etc. Meanwhile, the self-developed products include molecular diagnostic products to guide personalized medicine for cardiovascular and cerebrovascular diseases, companion diagnostic products to guide tumor diagnosis and treatment, FISH products and circulating tumor cell (CTC) Autoanalyzer System, all these provide clinical diagnosis basis for precision medicine.The company has successfully developed over 160 genetic diagnostic products and multiple in vitro diagnostic (IVD) devices since 2014, among which 14 molecular diagnostic kits have obtained Medical Device Registration Certificates in Class III by National Medical Products Administration (NMPA) in China.

The company has won the following honorary awards: Hi-tech Enterprise, National Demonstration Center for Genetic Testing Technology Application, Hubei Demonstration Construction Enterprise on Intellectual Property , Specialized and New "Little Giant" Enterprise in Hubei Province, the third batch of Invisible Champion Cultivation Enterprises in the Subdivision Field of Pillar Industries in Hubei Province, "Enterprise Research and Development Center " in Wuhan, the first batch of Supported Enterprises for "1,000 Great Enterprises and 10, 000 Innovative Talents " Program, "Golden Seed" backup stock listed enterprise, annual “Gazelle Enterprise" from 2016 to 2021 in the East Lake Hi-tech Development Zone, Wuhan, the 1st prize of Science and Technology Progress Award in Shandong Province and Hubei Province, the second prize of China Medical Science and Technology Award in 2021.

With a R&D center of 2,000㎡and GMP-accredited industrialized workshop of 3,200㎡, YZY Med obtained the Medical Device Production Licence" issued by Hubei Food and Drug Administration, and passed the standard attestation of ISO13485:2016.The following innovative products has passed the European Union (CE) certification: 14 kinds of genetic detection kits on cardiovascular pharmacogenome and tumor-targeted companion diagnosis.

The company has established a complete solution on genetic detection and precise treatment of personalized medication for cardiovascular diseases. With over 10 years of technical accumulation and clinical application, the company has become the leading enterprise in this subdivided field, ranking first in the domestic market with a testing volume of over 1.5 million people/time. The company will continue to launch new products into the market, vigorously promote technology optimization and platform upgrading to consolidate the leading position in this subdivided market.

Tumor companion diagnosis has a market value of 10 billion yuan, the company is one of the very few companies with the most complete product line in this segment. Through continuous technical accumulation and optimization with market validation, YZY Med has maintained a rapid sales growth in this sub-segment with a testing volume of 100,000 people/time. The company will further improve the product layout in this direction, to become the top enterprise on the genetic detection of tumor companion diagnostics.

The company is the first domestic leading enterprise to carry out independent self-development and market application of liquid biopsy technology. The automated CTC Autoanalyzer System CTCBIOPSY^® with the core technology was the first to obtain the Class II registration certificate by National Medical Products Administration(NMPA) in China, over 30,000 clinical data validation have been completed. The company continues to maintain the leading position in the field of liquid biopsy through solid technical accumulation and clinical data. On this basis, the company will continue to promote the extensive application of CTCBIOPSY^® and exosomes in the tumor subdivision and Immunotherapeutic field, thus to provide accurate and effective diagnosis and treatment scheme for clinicians and cancer patients.

About YZY MED

Company Profile

About YZYMED

Business Achievement